10-119672373-C-T
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM2PM5PP3_ModeratePP5_Very_Strong
The NM_004281.4(BAG3):c.626C>T(p.Pro209Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P209A) has been classified as Likely pathogenic.
Frequency
Consequence
NM_004281.4 missense
Scores
Clinical Significance
Conservation
Publications
- dilated cardiomyopathyInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- dilated cardiomyopathy 1HHInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- myofibrillar myopathyInheritance: AD Classification: DEFINITIVE Submitted by: G2P, ClinGen
- myofibrillar myopathy 6Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics
- familial isolated dilated cardiomyopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Charcot-Marie-tooth disease, axonal, type 2JJInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- distal hereditary motor neuropathyInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| BAG3 | ENST00000369085.8 | c.626C>T | p.Pro209Leu | missense_variant | Exon 3 of 4 | 1 | NM_004281.4 | ENSP00000358081.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Myofibrillar myopathy 6 Pathogenic:4Other:1
- -
This mutation has been previously reported as disease-causing and was found once in our laboratory as a de novo change in a 4-year-old male with muscular weakness, tight heel cords, restrictive cardiomyopathy. -
The heterozygous p.Pro209Leu variant was identified by our study in one individual with myofibrillar myopathy. Trio exome analysis showed this variant to be de novo. The p.Pro209Leu variant is pathogenic based off of our findings, multiple de novo reports in ClinVar, and the literature. -
- -
The missense variant c.626C>T (p.Pro209Leu) in the BAG3 gene has been reported previously in heterozygous state in individuals affected with myofibrillar myopathy and cardiomyopathy. Experimental studies have shown that this missense change affects protein function (Kimura et al., 2021; D'Avila et al., 2016). This variant is absent in the gnomAD Exomes. It is submitted to ClinVar as Pathogenic (Multiple submitters). The amino acid Proline at position 209 is changed to a Leucine changing protein sequence and it might alter its composition and physico-chemical properties. Multiple lines of computational evidence (Polyphen - Damaging, SIFT - Damaging and MutationTaster - Disease causing) predict a damaging effect on protein structure and function for this variant. The amino acid change p.Pro209Leu in BAG3 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:3
- -
Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 23341456, 26545904, 21423662, 30105547, 29338979, 30384889, 27321750, 22734908, 25728519, 21898660, 21361913, 19085932, 28831623, 27443559, 30023292, 28224639, 30061062, 30145633, 29552495, 30499714, 30559338, 29405094, 25273835, 32472079, 32453099) -
- -
Peripheral neuropathy Pathogenic:1
- -
Myofibrillar myopathy 6;C3151293:Dilated cardiomyopathy 1HH Pathogenic:1
This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 209 of the BAG3 protein (p.Pro209Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with myofibrillar myopathy (PMID: 19085932, 20605452, 21361913, 22734908, 25208129, 25728519, 26545904, 27443559). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 5981). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on BAG3 protein function. Experimental studies have shown that this missense change affects BAG3 function (PMID: 19085932, 21898660, 25273835, 27321750, 27443559). This variant disrupts the p.Pro209 amino acid residue in BAG3. Other variant(s) that disrupt this residue have been observed in individuals with BAG3-related conditions (PMID: 25208129, 27164712), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The p.P209L pathogenic mutation (also known as c.626C>T), located in coding exon 3 of the BAG3 gene, results from a C to T substitution at nucleotide position 626. The proline at codon 209 is replaced by leucine, an amino acid with similar properties. This alteration has been reported in numerous individuals with myofibrillar myopathy and was found to be de novo in these individuals (Selcen D et al. Ann Neurol, 2009 Jan;65:83-9; Jaffer F et al. J Peripher Nerv Syst, 2012 Jun;17:210-6; Lee HC et al. Clin Genet, 2012 Apr;81:394-8; Kostera-Pruszczyk A et al. J Muscle Res Cell Motil, 2015 Dec;36:423-32; Konersman CG et al. Neuromuscul Disord, 2015 May;25:418-22; D'Avila F et al. J Muscle Res Cell Motil, 2016 06;37:101-15; Vasilescu C et al. J Am Coll Cardiol, 2018 11;72:2324-2338; Andersen AG et al. Neuromuscul Disord, 2018 09;28:798-801; Schänzer A et al. Mol Genet Metab, 2018 03;123:388-399; Kim SJ et al. Genes Genomics, 2018 12;40:1269-1277; Noury JB et al. Muscle Nerve, 2018 02;57:330-334; Herman I et al. Muscle Nerve, 2021 03;63:304-310; Zhan L et al. Medicine (Baltimore), 2022 Jan;101:e28484). In vivo studies showed this alteration impacts protein function (Kimura K et al. Nat Commun, 2021 06;12:3575). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by BayesDel in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at